1. Home
  2. SF vs PCVX Comparison

SF vs PCVX Comparison

Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stifel Financial Corporation

SF

Stifel Financial Corporation

SELL

Current Price

$70.99

Market Cap

10.6B

Sector

Finance

ML Signal

SELL

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

SELL

Current Price

$59.41

Market Cap

7.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SF
PCVX
Founded
1890
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6B
7.0B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
SF
PCVX
Price
$70.99
$59.41
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$80.88
★ $116.40
AVG Volume (30 Days)
1.4M
★ 1.7M
Earning Date
10-21-2026
11-04-2026
Dividend Yield
★ 1.87%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 4.23
N/A
Revenue
★ $6,347,533,000.00
N/A
Revenue This Year
$7.50
N/A
Revenue Next Year
$7.90
N/A
P/E Ratio
$17.17
★ N/A
Revenue Growth
★ 6.65
N/A
52 Week Low
$65.40
$42.40
52 Week High
$134.74
$90.75

Technical Indicators

Market Signals
Indicator
SF
PCVX
Relative Strength Index (RSI) 50.37 42.72
Support Level $68.47 $58.85
Resistance Level $71.29 $62.44
Average True Range (ATR) 1.84 2.93
MACD 0.41 -0.39
Stochastic Oscillator 56.13 1.68

Price Performance

Historical Comparison
SF
PCVX

About SF Stifel Financial Corporation

Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a Saint Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: